Join
Live feed
·
PRReleasevia Quantisnow
Contineum Therapeutics Inc. logo

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

ByQuantisnow·Wall Street's wire, on your screen.
CTNM· Contineum Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTNM (Contineum Therapeutics Inc.) and more on Quantisnow.